Archives of Pharmacal Research

The Pharmaceutical Society of Korea (대한약학회)
권호 표지

Synthesis of Decapeptide of L-Aspartic Acid and Benzyl-L-Aspartic Acid by Solid Phase Peptide Synthesis

  • Published : 2005.07.01
Download PDF
⟨ Previous Next ⟩

Abstract

Polyene macrolide amphotericin B (AmB) is the drug of choice for the treatment of disseminated fungal infections. However, because of its pronounced side effects, the drug has limited applicability. There are few interesting reports, which state that co-administration of the drug with homo-peptide of polyaspartic acid reduces the side effects of the drug. In our present study, an approach has been made to systematically synthesize low molecular weight heteropeptides consisting of L-aspartic acid and its derivative. It was hypothesized that such heteropeptides will reduce the toxic side effects of the drug by facile hydrophobic binding between the polymer and the drug. We have employed the strategy of solid phase peptide synthesis (SPPS) to synthesize low molecular weight hetero-peptides by using L-aspartic acid and benzyl-L-aspartic acid to induce the hydrophobic binding between the peptide and the drug. In future, the proposed methodology can be employed to tailor other polypeptides substituted with benzyl groups to reduce the nephrotoxicity of AmB.

Keywords

References

  1. Berman, J. D., Human leishmaniasis: clinical, diagnostic, and chemotherapeutic developments in the last 10 years. Clin. Infect. Dis., 24, 684-703 (1997) https://doi.org/10.1093/clind/24.4.684
  2. Bodey, G. P., Anaissie, E. J., Elting, L. S., Estey, E., O'Brien, S., and Kantarjian, H., Antifungal prophylaxis during remission induction therapy for acute leukemia: fluconazole versus intravenous amphotericin B. Cancer, 73, 2099-2106 (1994) https://doi.org/10.1002/1097-0142(19940415)73:8<2099::AID-CNCR2820730814>3.0.CO;2-N
  3. Borowski, E., Novel approaches in the rational design of antifungal agents of low toxicity. Farmaco, 55, 206-208 (2000) https://doi.org/10.1016/S0014-827X(00)00024-0
  4. Brajtburg, J., Powderly, W. G., Kobayashi, G. S., and Madoff, G., Amphotericin B: delivery systems. Antimicrob. Agents Chemother., 34, 381-384 (1990) https://doi.org/10.1128/AAC.34.3.381
  5. Branch, R. A., Prevention of amphotericin B-induced renal impairment: a review on the use of sodium supplementation. Arch. Intern. Med., 148, 2389-2394 (1988) https://doi.org/10.1001/archinte.148.11.2389
  6. Brime, B., Molero, G.., Frutos P., and Frutos, G.., Comparative therapeutic efficacy of a novel lyophilized amphotericin B lecithin-based oil-water microemulsion and deoxycholateamphotericin B in immunocompetent and neutropenic mice infected with Candida albicans. Eur. J. Pharm. Sci., 22, 451- 458 (2004) https://doi.org/10.1016/j.ejps.2004.04.008
  7. Carpino, L. A. and Han, G.. Y., 9-Fluorenylmethoxycarbonyl amino-protecting group. J. Org. Chem., 37, 3404-3409 (1972) https://doi.org/10.1021/jo00795a005
  8. Chernushevich, I. V., Loboda, A. V., and Thomson, B. A., An introduction to quadrupole.time-of-flight mass spectrometry. J. Mass Spectrom., 36, 849.865 (2001) https://doi.org/10.1002/jms.207
  9. Kaloyanides G. J., Antibiotic-related nephrotoxicity. Nephrol. Dial. Transplant., 9 (suppl 4), 130-134 (1994)
  10. Kishore, B. K., Kallay Z, Lambricht P, Laurent G, and Tulkens P. M., Mechanism of protection afforded by polyaspartic acid against gentamycin-induced phospholipidosis I. Polyaspartic acid binds gentamicin and displaces it from negatively charged phospholipid layers in vitro. J. Pharmacol. Exp. Ther., 255, 867-874 (1990a)
  11. Kishore, B. K., Lambricht, P., Laurent, G., Maldague, P., Wagner, R., and Tulkens, P. M., Mechanism of protection afforded by polyaspartic acid against gentamicin-induced phospholipidosis II. Comparative in vitro and in vivo studies with poly-L-aspartic, poly-L-glutamic, and poly-D-glutamic acids. J. Pharmacol. Exp. Ther., 255, 875-885 (1990b)
  12. Mann, M., Hendrickson, R. C., and Pandey, A., Analysis of proteins and proteomes by mass spectrometry. Annu. Rev. Biochem., 70, 437-473 (2001) https://doi.org/10.1146/annurev.biochem.70.1.437
  13. Merrifield, R. B., Solid phase peptide synthesis: the synthesis of a tetrapeptide. J. Am. Chem. Soc., 85, 2149-2154 (1963) https://doi.org/10.1021/ja00897a025
  14. Meyer, R. D., Young, L. S., Armstrong, D., and Yu, B., Aspergillosis complicating neoplastic disease. Am. J. Med., 54, 6-15 (1973) https://doi.org/10.1016/0002-9343(73)90077-6
  15. Miranda, L. P. and Alewood, P. F., Accelerated chemical synthesis of peptides and small proteins. Proc. Natl. Acad. Sci. U.S.A., 96, 1181-1186 (1999) https://doi.org/10.1073/pnas.96.4.1181
  16. Mullen, A. B., Carter, K. C., and Baillie, A. J., Comparison of the efficacies of various formations of amphotericin B against murine visceral leishmaniasis. Antimicrob. Agents Chemother., 41, 2089-2092 (1997)
  17. Saxena, S. and Ghosh, P. C., Biodistribution of amphotericin B when delivered through cholesterol hemisuccinate vesicles in normal and A. fumigatus infected mice. Pharm. Res., 17, 1236-1242 (2000) https://doi.org/10.1023/A:1026418814417
  18. Sheppard, R. C., Modern methods of solid-phase peptide synthesis. Science Tools, 33, 122-129 (1986)
  19. Townsend, R. W., Zutshi, A., and Bekersky, I., Biodistribution of 4-[(14) C] cholesterol-Ambisome following a single intravenous administration to rats. Drug Metb. Dispos., 29. 681- 685 (2001)
  20. Warnock, D. W., Amphotericin B: an introduction. J. Antimicrob. Chemother., 28(Suppl. B), 27-38 (1991) https://doi.org/10.1093/jac/28.suppl_B.27
  21. Wiebe, V. J. and DeGregorio, M. W., Liposome-encapsulated amphotericin B: a promising new treatment for disseminated fungal infections. Rev. Infect. Dis., 10, 1097-1101 (1988) https://doi.org/10.1093/clinids/10.6.1097
  22. Whitelegge, J. P., Gundersen, C. B., and Faull, K. E., Electrosprayionization mass spectrometry of intact intrinsic membrane proteins. Protein Science, 7, 1423-1430 (1998) https://doi.org/10.1002/pro.5560070619